Advertisement

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

Takeshi Yamaura, Toshiyuki Nakatani, Ken Uda, Hayato Ogura, Wigyon Shin, Naoya Kurokawa, Koichi Saito, Norie Fujikawa, Tomomi Date, Masaru Takasaki, Daisuke Terada, Atsushi Hirai, Akimi Akashi, Fangli Chen, Yoshiya Adachi, Yuichi Ishikawa, Fumihiko Hayakawa, Shinji Hagiwara, Tomoki Naoe and Hitoshi Kiyoi

Article Information

PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 23, 2017
  • Accepted November 3, 2017
  • Published online December 5, 2017.

Article Versions


Contributors 
  • Takeshi Yamaura, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Toshiyuki Nakatani, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Ken Uda, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Hayato Ogura, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Wigyon Shin, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Naoya Kurokawa, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Koichi Saito, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Norie Fujikawa, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Tomomi Date, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Masaru Takasaki, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Daisuke Terada, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Atsushi Hirai, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Akimi Akashi, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;
  • Fangli Chen, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;
  • Yoshiya Adachi, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;
  • Yuichi Ishikawa, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;
  • Fumihiko Hayakawa, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;
  • Shinji Hagiwara, 1 Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan;
  • Tomoki Naoe, 3 National Hospital Organization Nagoya Medical Center, Nagoya, Japan
  • Hitoshi Kiyoi, 2 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output